Monday, October 29, 2018

New drug candidates reverse drug resistance in multiple myeloma in preclinical models

A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was recently reported. The study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM.

from Latest Science News -- ScienceDaily https://ift.tt/2z7xwvG
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists say most people need more protein than current guidelines suggest

A new review suggests that doing more exercise and eating more protein than current minimum recommendations may help people stay stronger, s...